Skip to main content
search

Conference: Bio-IT World Conference and Expo US 2026

Date: May 19 - 21, 2026

Location: Omni Boston Hotel at the Seaport in Boston, MA

Booth: 401

From molecule design and registration to first-in-human dose, the path from chemistry to clinic is ripe for earlier infusions of intelligence. What properties and bioactivity can we predict from structure alone? What could screening assays tell us about the clinical risks of off-target receptor interactions? And how can we use the combination of biosimulation and empirical PK/PD to select the optimal first-in-human dose and formulation?

At the same time, the profusion of modalities from small molecules to biomolecules to hybrids is pushing registration and compliance to become more exact and more flexible. How do we optimize those workflows so that they stay ahead of scientific discovery and evolving international regulations?

Where to hear Certara insights and Expertise

Wednesday, May 20 | 12:25-12:35pm
Featured presentation in the Generative AI Track: Model Lifecycle Management from Compound to Clinic

Presenters: Sean McGee, Director of Product, AI, Certara

The path from chemical entity to first-in-human dose traverses a chain of models, from QSAR to ADME. Hundreds of scientists rely on these models, but too often, it falls to a small team of data scientists and informaticists to oversee the environment where these models get trained, validated, deployed, updated, and archived. The need to move from “model lake” to manageable infrastructure is urgent.

In this session, Sean McGee, MS, Director of Product for Certara.AI, will introduce a framework for model lifecycle management, with particular attention to access, data flow, and model metadata. While machine learning forms the core of many of these models, Sean will also explain the role of Generative AI as the key to agentic workflows, where the outputs of one model automatically feed the next while the scientist stays firmly in the loop.

Sean McGee, MS

Director of Product, Certara

Sean McGee is currently the Director of Product at Certara, working within the Certara artificial intelligence (AI) group. Throughout his career, Mr. McGee has supported the strategy and go-to-market motions of various software technologies, including Benchling’s laboratory informatics platform and the AI and molecular modeling and simulation offerings for Dassault Systèmes BIOVIA brand. In his role with Certara, Mr. McGee guides the development of new AI-focused use cases which maximize the benefits of the Certara AI and broader company portfolio.

Mr. McGee completed his Master of Science at the University of Notre Dame exploring the scientific and commercial applications of medical devices designed to aid in the identification of child abuse.

 

Meet us there

Visit our booth to discuss these and related questions. While there, you can explore Certara solutions spanning:

  • compound design, registration, compliance and more with Chemaxon
  • self-service data access and analysis of structure-activity relationships with D360
  • new capabilities in biosimulation with Certara IQ™ and Simcyp®
  • Deep learning, data fabrics, agentic-inspired workflow design with Certara.AI

While at our booth, you can also RSVP for our cocktail reception on Wednesday, May 20th, from 6pm to 10pm at Del Friscos’s Double Eagle Steakhouse.

Let's discover a smarter way to advance therapies

Submit this form to share your interests and questions. We’ll respond with some meet-up ideas to get you in conversation with our relevant experts.